FDG PET/CT evaluation of treatment response in patients with recurrent colorectal cancer

Clin Nucl Med. 2011 Jan;36(1):11-6. doi: 10.1097/RLU.0b013e3181feeb48.

Abstract

Aim: to evaluate the treatment response in patients with recurrent colorectal cancer (CRC) using FDG PET/CT.

Materials and methods: a total of 32 recurrent CRC patients (21 males, 11 females; mean age, 52.8 years) were included in this retrospective study. All patients underwent a baseline and follow-up FDG PET/CT scans after chemotherapy. Of 32 patients, 23 patients had follow-up carcinoembryonic antigen (CEA) levels.

Results: on qualitative analysis of baseline and follow-up FDG PET/CT studies, there were 20 nonresponders and 12 were responders. On quantitative analysis, there were 19 nonresponders and 13 were responders. In responders, baseline and follow-up mean SUV(max) were 11.8 ± 10.1 and 3.7 ± 4.1, respectively (significant decrease, P = 0.001). Among nonresponders, baseline and follow-up mean SUV(max) were 8.1 ± 5.2 and 14.1 ± 9.0, respectively (significant increase, P = 0.003). There was no association between response and different factors like age, sex, diagnosis, extent of the lesions, and number of lesions.

Conclusion: FDG PET/CT appears to be useful modality in evaluating chemotherapy response and can differentiate responders from nonresponders in recurrent CRC patients.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Colorectal Neoplasms / diagnostic imaging*
  • Colorectal Neoplasms / drug therapy
  • Female
  • Fluorodeoxyglucose F18* / pharmacokinetics
  • Humans
  • Male
  • Middle Aged
  • Positron-Emission Tomography*
  • Recurrence
  • Tomography, X-Ray Computed*
  • Treatment Outcome

Substances

  • Fluorodeoxyglucose F18